Filing Details

Accession Number:
0001104659-21-005833
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-01-20 16:16:17
Reporting Period:
2021-01-19
Accepted Time:
2021-01-20 16:16:17
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1722964 Y-Mabs Therapeutics Inc. YMAB () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1106519 N David Gill C/O Y-Mabs Therapeutics, Inc.
230 Park Avenue Suite 3350
New York NY 10169
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-01-19 2,000 $11.16 2,000 No 4 M Direct
Common Stock Disposition 2021-01-19 2,000 $46.52 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Employee Stock Option (right to buy) Disposition 2021-01-19 2,000 $0.00 2,000 $11.16
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
24,000 2028-04-24 No 4 M Direct
Footnotes
  1. The option exercise and sale transaction reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
  2. This transaction was executed in multiple trades at prices ranging from $45.9500 to $47.6800. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
  3. Stock option granted to the Reporting Person as a non-employee director pursuant to the 2015 Equity Incentive Plan of Y-mAbs Therapeutics, Inc.
  4. The stock option was (a) granted on April 24, 2018 pursuant to the 2015 Equity Incentive Plan of Y-mAbs Therapeutics, Inc., and (b) represents the right to purchase a total of 32,000 shares of common stock; and (c) vests and becomes exercisable in equal monthly installments until the third anniversary of the date of grant subject to continued service through such dates and unless vesting is accelerated pursuant to the terms of the grant.